

INSMED INC  
Form 8-K  
July 22, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 22, 2013**

**INSMED**  
**INCORPORATED**

(Exact name of registrant as specified in its charter)

**Virginia**  
(State or other jurisdiction of  
incorporation)

**0-30739**  
(Commission File Number)

**54-1972729**  
(I.R.S. Employer Identification No.)

**9 Deer Park Drive, Suite C,**  
**Monmouth Junction, New Jersey**  
(Address of principal executive offices)

**08852**  
(Zip Code)

Registrant's telephone number, including area code: **(732) 997-4600**

**Not Applicable**

## Edgar Filing: INSMED INC - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On July 22, 2013, Insmmed, Inc. (the Company ) issued 6,900,000 shares of its common stock par value \$0.01 per share pursuant to an underwriting agreement, dated July 16, 2013 (the Underwriting Agreement ) with Leerink Swann LLC, as representative of the several underwriters. The number of Shares sold by the Company reflects the underwriters' exercise in full of their over-allotment option. The offering of the Shares was registered under the Securities Act of 1933, as amended, pursuant to the Company's shelf registration statement on Form S-3 (Registration No. 333-188851).

The opinion of Hunton & Williams LLP relating to the validity of the shares offered and sold pursuant to the Underwriting Agreement, is filed as Exhibit 5.1 to this report and incorporated herein by reference.

On July 22, 2013, the Company issued a press release announcing the closing of the offering of the Shares and the underwriters' exercise in full of their over-allotment option. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
5.1	Opinion of Hunton & Williams.
23.1	Consent of Hunton & Williams (included in Exhibit 5.1).
99.1	Press Release dated July 22, 2013.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 22, 2013

INSMED INCORPORATED

By:	/s/ Andrew T. Drechsler
Name:	Andrew T. Drechsler
Title:	Chief Financial Officer

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
5.1	Opinion of Hunton & Williams.
23.1	Consent of Hunton & Williams (included in Exhibit 5.1).
99.1	Press Release dated July 22, 2013.